1 pixel 1 empty pixel
News on laptop and phone

Vaughan-Based Revive Therapeutics Engages NYU School of Medicine for Cystinuria Phase 2 Study

VAUGHAN, ONTARIO--(Marketwired - Dec. 21, 2016) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on commercializing treatments for rare diseases such as Cystinuria and Wilson's disease, today announced it has engaged NYU School of Medicine as one of the Company's clinical sites in the U.S. for its Phase 2 clinical study for Cystinuria.

VAUGHAN, ONTARIO–(Marketwired – Dec. 21, 2016) – Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on commercializing treatments for rare diseases such as Cystinuria and Wilson’s disease, today announced it has engaged NYU School of Medicine as one of the Company’s clinical sites in the U.S. for its Phase 2 clinical study for Cystinuria.

“I am very pleased to have NYU School of Medicine as a clinical site for our Phase 2 clinical study for Cystinuria,” said Fabio Chianelli, President of Revive. “We are fortunate to have established a relationship with one of the leading institutions that provides treatment for Cystinuria and to have David S. Goldfarb, MD, professor of medicine and neuroscience and physiology at NYU School of Medicine, as the Principal Investigator for the entire study and Lama Nazzal, MD, assistant professor of medicine at NYU School of Medicine, as the Principal Investigator at the site.”

Full Article: www.marketwired.com